标题
Managing children with chronic myeloid leukaemia (CML)
作者
关键词
-
出版物
BRITISH JOURNAL OF HAEMATOLOGY
Volume 167, Issue 1, Pages 33-47
出版商
Wiley
发表日期
2014-07-01
DOI
10.1111/bjh.12977
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment
- (2013) Bernadette Anna Sophia Jaeger et al. MEDICAL SCIENCE MONITOR
- How I treat CML blast crisis
- (2012) R. Hehlmann BLOOD
- Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia
- (2012) Manuela Krumbholz et al. GENES CHROMOSOMES & CANCER
- Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty
- (2012) F. Giona et al. HAEMATOLOGICA
- Haematological cancers in pregnancy
- (2012) Benjamin Brenner et al. LANCET
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
- (2012) B Hanfstein et al. LEUKEMIA
- Standardized definitions of molecular response in chronic myeloid leukemia
- (2012) N C P Cross et al. LEUKEMIA
- Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
- (2011) A. Fabarius et al. BLOOD
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
- (2011) S. Soverini et al. BLOOD
- How I treat childhood CML
- (2011) J. R. Andolina et al. BLOOD
- Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
- (2011) A. R. Ibrahim et al. BLOOD
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Mutational analysis in chronic myeloid leukemia: when and what to do?
- (2011) Susan Branford et al. CURRENT OPINION IN HEMATOLOGY
- Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial
- (2011) Frédéric Millot et al. JOURNAL OF CLINICAL ONCOLOGY
- Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
- (2011) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium
- (2011) Richard Aplenc et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
- (2011) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with Chronic Myeloid Leukemia
- (2011) Haruko Shima et al. JOURNAL OF PEDIATRICS
- Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model
- (2011) Beate Schultheis et al. LEUKEMIA RESEARCH
- Imatinib has adverse effect on growth in children with chronic myeloid leukemia
- (2011) Deepak Bansal et al. PEDIATRIC BLOOD & CANCER
- Treatment of Pediatric Chronic Myeloid Leukemia in the Year 2010: Use of Tyrosine Kinase Inhibitors and Stem-Cell Transplantation
- (2011) M. Suttorp et al. Hematology-American Society of Hematology Education Program
- Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
- (2010) T. P. Hughes et al. BLOOD
- Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study
- (2010) Giuseppe Saglio et al. CANCER
- Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
- (2010) N. P. Shah et al. HAEMATOLOGICA
- Comparative In Vitro Cellular Data Alone Are Insufficient to Predict Clinical Responses and Guide the Choice of BCR-ABL Inhibitor for Treating Imatinib-Resistant Chronic Myeloid Leukemia
- (2010) Pierre Laneuville et al. JOURNAL OF CLINICAL ONCOLOGY
- Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
- (2010) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
- (2010) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
- (2010) D Bixby et al. LEUKEMIA
- Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy
- (2010) Qaiser Bashir et al. LEUKEMIA & LYMPHOMA
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy
- (2010) Susan L. Hobernicht et al. PEDIATRIC BLOOD & CANCER
- Management of Drug Toxicities in Chronic Myeloid Leukaemia
- (2009) Michael J. Mauro et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- CML in pregnancy and childhood
- (2009) Jane Apperley BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Current Status and Perspectives of Tyrosine Kinase Inhibitor Treatment in the Posttransplant Period in Patients with Chronic Myelogenous Leukemia (CML)
- (2009) Evgeny Klyuchnikov et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors: The Japan Marrow Donor Program
- (2009) Hideki Muramatsu et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
- (2009) S. Soverini et al. BLOOD
- Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
- (2009) S. Saussele et al. BLOOD
- Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
- (2009) L. Noens et al. BLOOD
- Does a rise in theBCR-ABL1transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
- (2009) David Marin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib
- (2009) H. Schmid et al. HAEMATOLOGICA
- Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response
- (2009) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- (2009) Michele Baccarani et al. JOURNAL OF CLINICAL ONCOLOGY
- Allogeneic Stem Cell Transplantation for Pediatric and Adolescent Patients with CML: Results from the Prospective Trial CML-paed I
- (2009) M. Suttorp et al. KLINISCHE PADIATRIE
- Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia
- (2009) J E Cortes et al. LEUKEMIA
- Imatinib mesylate causes growth plate closure in vivo
- (2009) K Vandyke et al. LEUKEMIA
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
- (2009) A Hochhaus et al. LEUKEMIA
- Prolonged chronic phase of greater than 10 years of chronic myelogenous leukemia in a patient with congenital human immunodefeciency virus infection
- (2009) Bhuvana A. Setty et al. PEDIATRIC BLOOD & CANCER
- Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
- (2008) S. J. Lee et al. BLOOD
- The effects of imatinib on pregnancy outcome
- (2008) S. M. Pye et al. BLOOD
- European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
- (2008) D. Marin et al. BLOOD
- Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
- (2008) K. Porkka et al. BLOOD
- Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression
- (2008) Jamshid S. Khorashad et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis
- (2008) Hugues de Lavallade et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
- (2008) Sara Redaelli et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now